The University Of Auckland

The University Of Auckland Research Office Division, a state-controlled international higher-education institution based in Auckland, New Zealand, participates in federal research contracting and grant-funded research as a prime recipient and subcontractor, delivering biomedical and basic science research across defense, health, and civilian agencies without set-aside designations.

The University Of Auckland competes in full-and-open federal research procurements, holding no SBA certifications. Recent prime contracting work includes three definitive-contract awards from the Food and Drug Administration: a $298,583 contract to evaluate the applicability of a robotic soft esophagus device in assessing opioid drug swallowability (awarded September 2021, completed December 2023); a $554,827 contract to develop in-vitro tools simulating pharmaceutical opioid drug chewing (awarded September 2021, ultimate completion March 2025); and a $109,371 purchase order from NASA's Shared Services Center for research and development (awarded October 2021, completed June 2022). The university operates as a subsidiary through Auckland Uniservices LIMITED, a foreign-owned not-for-profit organization supporting commercialization and research services.

Federal grant funding dominates the university's recent portfolio. The Office of Naval Research has awarded nine grants totaling substantial combined value for deep-diving physiology and detection research, including a current three-year project on EEG monitoring and hydrogen breathing in deep diving ($171,440, awarded March 2026 through February 2029) and prior work on oxygen toxicity prediction using diver EEG recordings and beaked whale genotyping for population impact assessment. The Defense Health Agency has funded four grants for biomedical research: a $1.126 million award for identifying earliest druggable targets in Parkinson's disease (September 2024 through August 2027), a $130,000 award for cell-based model development in paraganglioma and pheochromocytoma tumor suppressor research (October 2025 through September 2027), and a $534,258 award for electroceutical treatment and electrical biomarker research in spinal cord injury (September 2023 through August 2026). The Department of the Air Force and Air Force Research Laboratory have funded basic research in convex optimization for space situational awareness and point process spatiotemporal dependency structures. The Bureau of East Asian and Pacific Affairs has funded symposium and public engagement grants on democracy and STEM outreach, including an Opportunity Rover roadshow delivered nationwide in New Zealand (May through December 2024).

Across the top five customer agencies by award count — the Office of Naval Research (12 awards), the Navy (10 awards), the National Institute of Neurological Disorders and Stroke (6 awards), the National Institute of Biomedical Imaging and Bioengineering (5 awards), and the Air Force (5 awards) — these agencies account for 48 percent of all awards. The FDA leads potential-value rankings with $1.1 million across three awards; the Office of Naval Research and Navy awards together account for the largest portion of award volume. Combined obligated federal dollars across all awards reach $24.5 million, substantially exceeding the $1.4 million combined potential value and reflecting amendment and modification activity on long-duration grants.

The university's subcontractor role spans collaborative biomedical and clinical research under prime recipients including the Cleveland Clinic Lerner College of Medicine (knee joint biomechanics consensus modeling), Yale University (transcranial magnetic stimulation and motor neuron excitability studies), Wake Forest University Health Sciences (smoking cessation and lung health cohort studies in New Zealand), the University of Pennsylvania (PRECISION-HEAL data mapping and visualization for pain research), Vanderbilt University Medical Center (statistical methods for HIV/AIDS research), the University of Washington (reproducible systems for biomedical modeling), and Louisiana State University (nano-agrochemical environmental fate and soil organism impact studies). Most recent sub-award activity (2025–2026) involves biomechanical modeling and transcranial magnetic stimulation leadership for U.S. clinical trial sites, with the university providing remote data processing, certification, and quality assurance while conducting on-site participant recruitment and data collection in New Zealand.

Activity expanded sharply from 2 awards in 2022 to 16 in 2024, then contracted to 7 awards in 2025 and 4 in 2026 year-to-date. Two awards reach ultimate completion within the next twenty-four months, representing minimal recompete exposure in that window. Service Contract Inventory records capture minimal SCI-reportable invoiced activity, with $75 thousand across FY2022 at 1.0 FTE, reflecting that the majority of the university's federal funding flows through grant mechanisms rather than service-contract instruments above the $150,000 SCI threshold. The University Of Auckland operates as a 63 percent prime, 37 percent sub participant across all federal awards, positioning it as a research collaborator and sub-recipient embedded in larger U.S. institutional networks rather than as an independent federal contractor.